PND6 THE IMPACT OF SPECIALTY CARE PROGRAMS ON RELAPSES OF MULTIPLE SCLEROSIS USING ADMINISTRATIVE DATA  by Tang, J. et al.
moderate and high anticholinergic activity respectively. Frequency of the use of
drugs having anticholinergic activity prescribed along with cholinesterase inhibi-
tors and NMDA receptor antagonist was compared using the Chi square test.
RESULTS: Of the patients with AD, 654 patients were given cholinesterase inhibi-
tors and NMDA receptor antagonist. Most of the AD patients were prescribed with
cholinesterase inhibitors (86.69%) as compared to NMDA receptor antagonist
(14.83%). 98.94% of patients on cholinesterase inhibitors and 93.82% on NMDA
receptor antagonist were co-prescribed drugswith anticholinergic properties. Sim-
ilar percent of patients on cholinesterase inhibitors andNMDA receptor antagonist
were co-prescribed drugswithmild (65.43%vs 63.92%, p0.7723),moderate (22.40%
vs 21.65%, p0.8699) and high (11.11% vs 8.25%, p0.3990) anticholinergic activity.
No statistical difference in prescribing moderate to high anticholinergic agents for
treating Depression, Convulsions and Parkinson’s disease was found in AD pa-
tients being treated with cholinesterase inhibitors and NMDA receptor antagonist.
CONCLUSIONS: Patients with AD receiving cholinesterase inhibitors or NMDA re-
ceptor antagonist appear to be co-prescribed drugs havingmoderate and high level
of anticholinergic activity without any distinction. Physicians should be more pru-
dent in co-prescribing drugs with anticholinergic activity in patients with AD due
to the high risk of adverse reactions.
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OBJECTIVES: To study the prevalence of comorbid conditions in a population of
patients with Multiple Sclerosis (MS).METHODS: In a retrospective analysis, inte-
grated medical and pharmacy claims data (IMS LifeLink™ Health Plan Claims and
Longitudinal Prescriptions databases) were analyzed to select patients with an active
diagnosis of MS (ICD-9 code 340.*) during the 2009 calendar year. The presence of
comorbidities was also determined using ICD-9 codes present on medical claims.
Prescription drug use was evaluated by pharmacy claims and drug-specific billing
codes.RESULTS: From the database, 18,013 patientswithMSwere identified. About
two-thirds (67.6%) of patients were between 18 and 55 years of age, and 77.6%were
female. Evidence of specific chronic conditions was substantial and included: hy-
perlipidemia (seen in 36.1% of patients), HTN (32.9%), diabetes (10.8%), asthma
(8.3%), cardiac arrhythmias (7.2%), COPD (4.5%), and CHF (1.6%). The presence of
any respiratory conditions (asthma or COPD) was present in 11.4% of patients,
cardiovascular conditions (HTN, CHF, arrhythmias) in 37.3%, and metabolic condi-
tions (DM, HTN, hyperlipidemia) in 50.5%. Though the prevalence of many condi-
tions was age and gender dependent, their prevalence was independent of treat-
ments including disease-modifying treatments (DMTs) such as interferon,
glatiramer acetate, and natalizumab. CONCLUSIONS: This analysis illustrates the
complexity of the case-mix of patients with MS. An increasing amount of evidence
suggests that physical and mental comorbidities, and adverse health factors are
common and can affect the disease. Because of the high prevalence of comorbidi-
ties, any treatment decisions should be carefully considered and should be indi-
vidualized in order to optimize outcomes and reduce the potential interactions
between treatment and comorbidities.
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OBJECTIVES:Comorbidities in individualswithMSadd to the complexity of disease
management. A better understanding of the nature and prevalence of comorbid
illness in MSmay improve patient outcomes. The objective of this research was to
gain a better understanding of the comorbid illnesses present in individuals with
MS compared to individualswithoutMS.METHODS:TheNational Health andWell-
ness Survey (NHWS) is an Internet-based annual study of the healthcare attitudes
and behaviors of a US representative adult sample. Demographics and comorbidi-
ties were compared between individuals with diagnosed MS and individuals with-
out MS. RESULTS: Compared to subjects without MS, a greater proportion of sub-
jects with MS reported being female (64.3% vs. 51.3%; p0.001) and being white
(non-hispanic) (78.7% vs. 74.0%; p0.006). Subjects with MS reported more comor-
bidity compared to subjects without MS (Charlson Comorbidity Index: 0.97 vs. 0.82;
p0.001). Neurologic symptoms and conditions (pain 56.7% vs. 37.8%, headache
55.8% vs. 44.6%,migraine 29.5% vs. 16.4%, restless leg syndrome 18.7% vs. 7.8%, and
stroke 5.2% vs. 1.4%; p0.001), and psychiatric symptoms and conditions (sleep
difficulties 43.3% vs. 29.6%, depression 39.7% vs. 23.5%, anxiety 33.0% vs. 22.6%,
insomnia 28.5% vs. 17.8%, and panic disorder 8.2% vs. 3.6%; p0.001) were more
common in subjects with MS compared to those without MS. Rates for hyperten-
sion (33.6% vs. 32.8%; p0.968) and high cholesterol (32.3% vs. 30.9%; p0.669) were
similar but cardiovascular conditions such as angina (4.8% vs. 2.9%; p0.001), ar-
rhythmia (4.8% vs. 2.7%; p0.003), and peripheral arterial disease (3.7% vs. 1.4%;
p0.001) were higher for MS subjects. CONCLUSIONS: As expected, individuals
with MS have significant comorbid illness compared to individuals without MS.
Neurologic and psychiatric conditions and symptoms are common and typically
more prevalent inMS. Cardiovascular risk factors are similar to individualswithout
MS but higher rates of cardiovascular conditions were observed.
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OBJECTIVES: To understand how shift work disorder (SWD) affected the lives of
shift workers (SWs) and how SWD was diagnosed from the perspective of health
care professionals (HCPs) and SWs.METHODS: Two separate online surveys were
administered to: (1) SWs with/out SWD and (2) HCPs. Participation in the SWs
survey required 21 hours per week working shifts in the previous 2 weeks, a
diagnosis of SWD or10 score on the Epworth Sleepiness Scale (ESS), and5 score
on any of the subscales of the Sheehan Disability Scale (SDS). Participation in the
HCP survey required3 years in pre-designated specialties and at least 75% of their
time spent in patient care. RESULTS: A total of 260 respondents complete the SWs
survey and 673 the HCP survey. SWnegatively impacted respondents’ energy level,
social life, and emotional and physical health. SWs also reported a loss of concen-
tration (87%), mistakes (69%), and an injury (11%) at work. Many respondents used
caffeine and 57% of diagnosed respondents received prescription medication to
treat SWD symptoms. Of those SWs without diagnosed SWD, 23% denied having
excessive sleepiness despite scoring10 on the ESS and having functional impair-
ment (SDS). For those SWs who consulted with their HCPs, SWs initiated this con-
versation more than HCPs (82% vs. 13%). HCPs believe that 67% of total SWD is
never suspected by physicians and that 50% of SWD is undiagnosed because SWD
is oftenmasked by other conditions and/ormisdiagnosed.CONCLUSIONS:Respon-
dents reported that excessive sleepiness and insomnia associated with SW seri-
ously impacted their lives at home and at work. SWs do not always recognize their
SWD symptoms and are more likely to initiate a discussion of those symptoms
than HCPs. HCPs believe that SWD is often missed as it is masked by other comor-
bidities or misdiagnosed.
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OBJECTIVES: To assess Parkinson’s Disease (PD) progression using the Hoehn and
Yahr (H&Y) scale over the complete disease course based on systematic literature
reviewwithmeta-analysis. No systematic review of PD studies usingH&Yhas been
undertaken. Such findings could support models to evaluate economic effects of
disease modifying therapies. METHODS: A systematic literature review (PubMed)
was conducted to identify research since 1990 that reported longitudinal H&Y out-
comes to obtain progression time data. Reference lists from retrieved articles were
also reviewed and supplemented with recommendations from an expert neurolo-
gist. Statistical moments (e.g., survival at time t, median time to progress) were
extracted and expected time to progress to the subsequent stage was calculated
assuming a constant hazard rate of progression with a binomial distribution for
progression rates. Average time to progress through all stages of disease was cal-
culated. Random effects meta-analysis was performed to assess heterogeneity be-
tween studies between each stage in progression. RESULTS: Of 554 identified rel-
evant titles, 56 articles were reviewed. Ten studies, including one open label
extension (OLE) trial and nine cohort studies, reported longitudinal H&Y outcomes
for 3,687 patients observed over an average of 13.5 years.Weighted by study sample
sizes, expected time to progress from H&Y 1 to H&Y 5 was 162.1 months. The OLE
trial had longest expected total progression time (431.8 months, N110); other
studies ranged from 102.0 to 171.7 months. Time from H&Y stage 1–stage 2, 2–3,
3–4, and 4–5 were 32.3, 60.5, 42.9 and 26.4 months, respectively. Meta-analysis
indicated significant heterogeneity in progression time between studies (I295%).
Omitting single studies did not affect pooled estimates. CONCLUSIONS: Economic
assessment of impacts of PD disease modification can consider expected progres-
sion rates over the full course of the disease. Progression rates are most rapid from
H&Y stage 4 to 5.
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OBJECTIVES: Relapse reduction is important for multiple sclerosis (MS) because
relapses lead to faster deterioration of patient health status. This study aims to
evaluate the impact of specialty care programs which mainly focus on mail-order,
professional monitoring and assessment for MS patients nationwide, compared to
usual care. METHODS: Administrative claims for people with MS were extracted
from the databases from a pharmacy management company for this retrospective
cohort study. Enrollees with continuous pharmacy benefit eligibility were followed
for three years. Patients exposed to specialty care programs were classified as
specialty care group. Relapses were considered to have occurred when patients
used steroids or were hospitalized due to MS. The outcomemeasures included the
risk, number of relapses, and time to relapse. Logistic, negative binomial, and
Cox-proportional hazards regressions were performed to compare between
groups. RESULTS: Study cohort consisted of 1731 eligible MS patients, of which
1427 received the specialty care. During the study period, 1634 relapses were iden-
tified with amean annual relapse rate of 0.3 among specialty care group versus 0.4
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among usual care group. In the unadjusted model, specialty care was associated
with lower risk of developing MS relapses with risk ratios (RR) of 0.813 for any
relapse, 0.765 for multiple relapses, hazard ratios (HR) of 0.727 for the first relapse,
0.782 for the second relapse. After adjusting for the demographics, socioeconom-
ics, comorbidities, and health services utilizations, specialty care was associated
with lower risk of MS relapses with RRs of 0.761 for any relapses, 0.712 for multiple
relapses; lower HRs of 0.674 for the first relapse, and of 0.741 for the second relapse,
compared to usual care. These measures are mostly statistically significant (P
0.05). CONCLUSIONS: Over the three-year study period, specialty care was associ-
ated with significantly lower risk for relapses, fewer MS relapses, and longer re-
lapse-free time.
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OBJECTIVES: To estimate the prevalence of drug-treated MS within the Brazilian
public healthcare system (BPHS) and compare it with published prevalence rates.
METHODS: A previously described method to estimate the prevalence of diseases
treated with drugs that are specific to them and must be taken continuously was
employed. The total amount of MS drugs (Glatiramer 20mg, Betainterferon 22mcg,
Betainterferon 44mcg, Betainterferon 30mcg, Betainterferon 300mcg) dispensed
from 2006 to 2009 was obtained from the Ambulatory Information Database and
the daily doses defined by BPHS MS guidelines were used to convert it in drug-
treated cases. The drug-treated prevalence was compared with rates achieved
through conventional cross-sectional studies (4.27-15/100,000). Complementary
analysis was performed using Brazilian private health plans coverage data.
RESULTS: The estimated drug-treated prevalent cases within the BPHS were 3,569
in 2006 with a constant increasing until 2009 when reached 6,099. Drug-treated
prevalence rates (per 100,000) were 1.93, 2.63, 3.08, and 3.21 in 2006, 2007, 2008, and
2009, respectively. MS prevalent cases in the BPHS were estimated as ranging from
7,838 in 2006 to 8,113 in 2009 using the 4.27/100,000 rate and from 27,533 in 2006 to
28,499 in 2009 using the 15/100,000 rate. The prevalence of MS estimated from drug
consumption data was found to be 24.8-78.6% lower than that estimated from
cross-sectional studies. Even when private health plans coverage (
20%) was con-
sidered, the difference remained substantial between drug-treated and BPHS prev-
alent cases (total prevalent cases minus those supposed to have private coverage).
In 2009, this difference ranges from 310 (BPHS cases minus drug-treated cases)
to 22,399 (prevalent cases using 15/100,000 minus drug-treated). CONCLUSIONS:
These findings raise important questions about barriers to access to MS treatment,
undertreatment and/or underdiagnosis of MS and the reliability of the available
prevalence rates for use in projecting eligible population and performing budget
impact analysis.
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OBJECTIVES: To investigate the incidence of subarachnoid hemorrhage(SAH) in
patients with unruptured intracranial aneurysm(UIA) in South Korea from
2006-2009. METHODS: A longitudinal study using national representative health
claim database including all hospital records for every Korean citizen was em-
ployed. We identified patients with UIA who were 18-80 years old using ICD-10
codes of I67.1 in 2006. To select eligible patients, history period was applied for one
year from first diagnosis of UIA (i.e. index date) in 2006. We excluded patients with
UIA diagnosis, SAH, or treatments(clip and coil) during history periods. Patients
with head trauma or brain tumor during study periods were also excluded. Eligible
patients were followed for at least 3 years from index date. SAH patients were
defined as ICD-10 codes of I60 excluding I60.8 with the hospitalization of14days
or death within 14days from hospitalization. Sensitivity analysis was conducted to
see the robustness using different definition of SAH. Additionally, the length of stay
of SAH was estimated using generalized linear model with log link and gamma
distribution. RESULTS: We identified 7404 eligible patients with UIA, including
1,466(20%) treated patients and 5,938(80%) untreated patients formedian follow-up of
3.4 years. For patients with untreated UIA, the incidence rate of SAH was 0.7/100per-
son-years(PYs) (133/5,934 patients). In the definition of SAH of all hospitalization, the
incidence rate increased by 1.3/100PYs. The incidence of SAH was highest in the first
year after first diagnosis of UIA. Mean length of stay of SAH was 30days(95%CI:24.0-
36.2) formales and 38days(95%CI:32.8-42.8) for females, respectively.CONCLUSIONS:
The rupture rate for untreated UIA patients were 0.7-1.3/100 PY from 2006-2009.
This study results indicate that careful follow-up for UIA patients is needed to
prevent rupture and decrease economic burden of SAH.
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OBJECTIVES: To determine the effect of Alzheimer patient’s characteristics and
medications on their functional dependence to carry out activities of daily living
(ADL).METHODS: Data for the present study was obtained from National Nursing
Home Survey (NNHS-2004). Alzheimer patients selected using ICD9-CM code of
331.00. Patients aged above 65 with completed Minimum Data Set (MDS) assess-
ment were included in the study. Long formMDS-ADL scale ranging from 0-28 that
comprises sevenADLwas used for the study. Patientswho scored less than 15were
considered independent, while those who scored between15-28 were considered
dependent. Multivariate logistic regression was carried out to determine the effect
of patient demographics, geriatric conditions, co-morbidities and medication use
on functional dependence. Statistical analysis performed using SAS 9.1. RESULTS:
Among 166,382 Alzheimer patients, 61,094 (58.02%) were functionally dependent.
Being female (OR  1.743; 95%CI  1.131 - 2.685), presence of urinary incontinence
(OR  3.212; 95%CI  2.093 - 4.928), bowel incontinence (OR  6.384; 95% CI  4.318 -
9.439), presence of physical restraint (OR  1.960; 95% CI  1.367 - 2.809) and, poor
nutrition (OR2.015; 95%CI 1.447 - 2.806) significantly increased the risk of func-
tional dependence. Co-morbidities such as depression (OR 1.546; 95%CI 1.042 -
2.293) and osteoporosis (OR 1.644; 95%CI  1.054 - 2.562) increased the risk of
functional dependence while use of cholinesterase inhibitor (ChEI) decreased the
risk of functional dependence (OR  0.466; 95%CI  0.348 - 0.622). CONCLUSIONS:
Factors such as incontinence, poor nutrition, co-morbidities and physical restraint
use, in addition to cognitive impairment, significantly affect ability of Alzheimer
patients to carry out ADL. A multidimensional approach that controls these risk
factors may help decrease functional dependence in carrying out ADL.
Neurological Disorders – Cost Studies
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OBJECTIVES: To estimate the incremental budgetary change in per-member-per-
month (PMPM)medical and pharmacy costs after the introduction of everolimus, a
mammalian target of rapamycin inhibitor, for the treatment of subependymal gi-
ant-cell astrocytomas (SEGA) in patients with tuberous sclerosis complex. In a
phase I/II trial, everolimus was associated with reduced SEGA volume and seizure
frequency.METHODS: Two-year budget impact analysis was conducted based on a
retrospective, longitudinal study of administrative claims that showed an increase
in healthcare costs in the years leading up to and after surgery for SEGA removal.
Based on the aforementioned trial, themodel assumed that patients using everoli-
mus did not require surgical intervention; however, to be conservative, no impact
on seizure frequency was assumed. Estimates of SEGA prevalence, adverse events,
drug costs, and monitoring costs were based on published sources. Sensitivity
analysis evaluated the impact of estimating annual treatment costs for patients
with continuous eligibility only. RESULTS: In a hypothetical 1,000,000-member
health plan, an estimated 5.9 patients with growing SEGAs require care. Prior to
introducing everolimus, estimated total cost for the treatment of growing SEGAs
was $0.022 PMPM for all plan members. After introducing everolimus, there were
0.9, 19.8, and 6.6 fewer claims per patient for inpatient hospitalizations, outpatient
visits, and other pharmaceutical use, respectively. While pharmacy cost increased
by $0.038 PMPM, the total medical and pharmacy costs increased by only $0.026,
due to fewer SEGA surgeries. Sensitivity analysis showed greater savings in medi-
cal spending after the introduction of everolimus, resulting in a total spending
increase of $0.022 PMPM. CONCLUSIONS: Increased pharmaceutical spending in
the first two years of everolimus use was partially offset by savings in medical
costs. Potential additional savings in anti-epileptic drug spending may further off-
set the costs.
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OBJECTIVES: We determined the prevalence of OSA in patients with the specific
components of the metabolic syndrome (hypertension, hyperlipidemia and diabe-
tes). We also explored the incremental burden of OSA on health care utilization in
patientswith the specific components of themetabolic syndrome.METHODS:Data
were obtained from the Maryland Medicaid database for January 2001 through June
2006. These data contain all claims records for medical inpatient, outpatient, and
pharmacy services submitted to the state.We assigned beneficiaries into groups: hav-
ing any one of the components of the metabolic syndrome, to a cohort called “one
disease” (n7,086). Having any two of the three components the cohort called “two
diseases” (n6,774). Having all of the three components the cohort called “three dis-
eases” (n5,925). Medical utilization data were collected from the index date through
theendof the studyor the last dateof service,whichever occurredfirst.RESULTS:The
likelihood of getting OSA by disease cohort- Beneficiaries with any two compo-
nents of the metabolic syndrome or all three components had 2.10 and 3.24 times
respectively the likelihood of developing OSA compared to those with one compo-
nent alone. The average annualized medical utilization by OSA status in each
cohort, adjusted for age, gender, race, obesity, CCI scores, and number of days in
cohort. Beneficiaries who had the concomitant diagnosis of OSA had a significantly
higher number ofmedical services claims than thosewithout OSA; physician office
visits accounted for the largest share of medical utilization, followed by outpatient
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